Institution Directory

Clinical trials at University of Alabama at Birmingham

Sites in Birmingham, AL

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 5:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1236

Shown on this page

Current sort

Stored official records

Conditions: Multiple Myeloma
Interventions: Bortezomib, Cilta-cel, Daratumumab, Dexamethasone, Pomalidomide; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 419 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 19
States / cities: Birmingham, Alabama • Phoenix, Arizona • Stanford, California + 16 more

Conditions: Advanced Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma, Collecting Duct Carcinoma, Kidney Medullary Carcinoma, Metastatic Malignant Neoplasm in the Bone, Papillary Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8, Unclassified Renal Cell Carcinoma
Interventions: Biospecimen Collection, Bone Scan, Cabozantinib S-malate, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Questionnaire Administration, Radium Ra 223 Dichloride; Procedure · Drug · Other + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 47
States / cities: Birmingham, Alabama • La Jolla, California • Sacramento, California + 37 more

Conditions: Diabetic Retinopathy
Interventions: blood draw; Biological
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 21 Years to 98 Years
Enrollment: 104 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Breast Cancer
Interventions: Cardiac MRI; Diagnostic Test
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older · Female only
Enrollment: 403 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2032
U.S. locations: 66
States / cities: Birmingham, Alabama • Washington D.C., District of Columbia • Tampa, Florida + 52 more

Conditions: Head and Neck Cancer (H&N)
Interventions: Avive+ Intervention, Standard Closure (Control); Procedure
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Dental Implant
Interventions: Fully Guided (FG), Pilot Drill Guide (PDG); Procedure
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 85 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Acellular Dermal Matrix, Alveolar Mucosa
Interventions: Phase I dental implant placement with acellular dermis, Phase II dental implant uncovery with acellular dermis; Procedure
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 85 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Multiple Sclerosis
Interventions: Time Restricted Eating, Unrestricted eating; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 64 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Severe Tricuspid Regurgitation
Interventions: Edwards EVOQUE Tricuspid Valve Replacement (TTVR) System, Medtronic Intrepid™ Transcatheter Tricuspid Valve Replacement (TTVR) System; Device
Lead sponsor: Medtronic Cardiovascular; Industry
Eligibility: 18 Years and older
Enrollment: 1,186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2041
U.S. locations: 13
States / cities: Birmingham, Alabama • Phoenix, Arizona • Thousand Oaks, California + 9 more

Conditions: Non-Muscle Invasive Bladder Neoplasms
Interventions: Not listed
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 19
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 15 more

Conditions: Multiple Myeloma
Interventions: JNJ-79635322; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 30
States / cities: Birmingham, Alabama • Gilbert, Arizona • Duarte, California + 24 more

Conditions: Depressive Disorder, Major
Interventions: Esketamine, Intranasal Placebo, Midazolam, Oral Placebo; Drug · Other
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 258 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 10
States / cities: Birmingham, Alabama • Washington D.C., District of Columbia • Atlanta, Georgia + 7 more

About this University of Alabama at Birmingham institution page

What this page lists: ClinicalTrials.gov records that list University of Alabama at Birmingham in Birmingham, AL as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at University of Alabama at Birmingham

Filter and sort this campus

Stored official records

A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma

Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study

Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)

Understanding and Predicting Breast Cancer Events After Treatment

Evaluating Avive+ Soft Tissue Matrix for Prevention of Superficial Radial Nerve Morbidity Following Radial Forearm Free Flap Harvest

To Compare the Two Implant Placement Protocols to Evaluate Placement Accuracy and Post-operative Healing of the Implant

Assessment of Two Soft Tissue Augmentation Using Acellular Dermis Around Dental Implants

Understanding the Impact of Meal Timing on Neurological Health in Adults With Multiple Sclerosis

Transcatheter Tricuspid Valve Replacement With the Medtronic Intrepid™ Transcatheter Tricuspid Valve Replacement (TTVR) System in Severe Tricuspid Regurgitation

A Study to Assess Real-World Use and Outcomes of TAR-200 for Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) in the United States

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma

A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder

About this University of Alabama at Birmingham institution page